Compare Norwegian Cruise Line Holdings Ltd (NCLH) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Norwegian Cruise Line Holdings Ltd vs Sana Biotechnology Inc — how do they compare? Norwegian Cruise Line Holdings Ltd trades at $14.92 (market cap $7.07B), while Sana Biotechnology Inc trades at $3.24 (market cap $1.03B). The key difference: Norwegian Cruise Line Holdings Ltd is far larger — about 6.9× Sana Biotechnology Inc's market cap, and Sana Biotechnology Inc is trading nearer its 52-week high, Norwegian Cruise Line Holdings Ltd nearer its low. Which is the better fit depends on your goals.
| NCLH | SANA | |
|---|---|---|
Market Cap | $7.07B | $1.03B |
Sector | Consumer Cyclical | Health |
52-Week High | $26.94 | $5.92 |
52-Week Low | $14.79 | $2.68 |
Enterprise Value | $21.88B | $946.04M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Norwegian Cruise Line Holdings (NCLH) trades at $15.39, down 1.16% with bearish technical signals despite recent earnings beats. The company shows improving fundamentals with $9.83B revenue and $423M net income in 2025, while maintaining attractive valuation metrics including P/E of 9.33 and P/S of 0.74. Recent news highlights fuel cost pressures from rising oil prices, though the company continues fleet expansion with new waterpark and ship developments.
NCLH presents a mixed outlook with strong analyst support (50% buy ratings, $20.25 target) but faces near-term headwinds from fuel costs and yield pressures. The stock offers value appeal with discounted valuation, though high leverage and operational challenges require monitoring for sustained recovery.
SANA Biotechnology trades at $3.45, down 10.39% in the past 24 hours, reflecting bearish technical signals and negative profitability. The company reported a net loss of $244.17 million for 2025, with a price-to-book ratio of 6.68. Recent news includes investor conference presentations and a peer-reviewed publication in The New England Journal of Medicine highlighting clinical data.
Despite analyst consensus favoring a 'Buy' rating (81.82% of 11 analysts), the stock faces significant risks from negative cash flows, high losses, and potential fiduciary concerns. Upside hinges on successful clinical developments and improved financial performance, but current fundamentals suggest caution for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Norwegian Cruise Line Holdings Ltd
Norwegian Cruise Line is the world's third-largest cruise company by berths (at more than 62,000), operating 29 ships across three brands (Norwegian, Oceania, and Regent Seven Seas), offering both freestyle and luxury cruising. The company has redeployed its entire fleet as of May 2022. With eight passenger vessels on order among its brands through 2027 (representing 20,000 incremental berths), Norwegian is increasing capacity faster than its peers, expanding its brand globally. Norwegian sailed to around 500 global destinations before the pandemic.
Read more on NCLH →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
